Novo Nordisk wins EC approval for Wegovy pill as EU's first oral GLP-1
Novo Nordisk has secured European Commission marketing authorisation for Wegovy as a once-daily pill (oral semaglutide 25 mg), making it the first GLP-1 receptor agonist in tablet form approved for weight management across all EU member states. The decision follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use in May 2026 and extends the product's global regulatory footprint to five jurisdictions, after earlier approvals in the US, UK, UAE and Bahrain.
The authorisation covers adults with obesity (BMI of 30 kg/m² or above) or overweight (BMI of 27 kg/m² or above) with at least one weight-related comorbidity, used alongside dietary and lifestyle intervention. In the same action, the EC also approved a single-dose, ready-to-use pen for the higher-dose 7.2 mg injectable formulation of Wegovy.
Trial data and efficacy
The pill approval rests on the OASIS phase 3 clinical programme, with the pivotal OASIS 4 trial providing the core dataset. That 64-week study enrolled 307 adults with obesity or overweight with one or more comorbidities. Oral semaglutide 25 mg produced approximately 17% mean weight loss against 3% on placebo, and roughly one in three participants achieved 20% or more weight reduction on the treatment-product estimand. The separately approved 7.2 mg injection is positioned by Novo Nordisk as achieving 21% mean weight loss.
The tolerability profile was broadly consistent with the established injectable semaglutide class, with adverse-event-related discontinuations at 6.9% versus 5.9% on placebo, a difference the company describes as nearly comparable.
Mike Doustdar, president and chief executive of Novo Nordisk, said that for many people "a tablet may be a simpler and more acceptable way to start and continue treatment," framing the pill as an access and adherence tool rather than a purely clinical advance over the injected form.
Market context and competitive landscape
The oral route of administration is widely viewed as a meaningful commercial differentiator in the GLP-1 market, which has expanded rapidly since the approval of semaglutide and tirzepatide injections. Adherence to injectable regimens remains a known friction point for some patient populations, and a once-daily tablet could broaden uptake among those who are needle-averse or prefer a more discreet administration method.
Eli Lilly's tirzepatide programme, approved in the EU in injectable form under the brand name Mounjaro, does not yet have an oral formulation at a comparable regulatory stage in Europe. Novo Nordisk's move gives it a meaningful window in the oral obesity segment, though analysts will note that the pill's 17% weight loss figure trails the injectable 7.2 mg formulation's 21% headline figure, meaning prescribers will need to weigh route preference against the magnitude of effect.
Wegovy pill is already commercially available in the US, UK and UAE. Novo Nordisk has said it intends to launch in additional markets during the second half of 2026, with EU member state availability expected to follow national reimbursement negotiations, which have historically taken 12 to 24 months in larger European markets such as Germany and France. Reimbursement trajectory will be the critical near-term variable for investors monitoring the product's revenue ramp in Europe.